+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Oral Mucositis - Pipeline Review, H2 2020

  • ID: 5146915
  • Drug Pipelines
  • August 2020
  • Region: Global
  • 66 pages
  • Global Markets Direct

FEATURED COMPANIES

  • Alivio Therapeutics Inc
  • BIOCND Inc
  • Clevexel Pharma SAS
  • Humanetics Corp
  • Lakewood-Amedex Inc
  • Matrix Biomed Inc
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Oral Mucositis - Pipeline Review, H2 2020, provides an overview of the Oral Mucositis (Gastrointestinal) pipeline landscape.

Oral mucositis is the most common type of mucositis. It is a debilitating complication of cancer surgery, chemotherapy and radiation. Symptoms include change in color, hyposalivation, a change in the integrity of the mucosa and the presence of edema on the lips and/or the tongue. Treatment included oral decontamination (mouth care) and oral debridement.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Oral Mucositis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Oral Mucositis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Oral Mucositis (Gastrointestinal) pipeline guide also reviews the key players involved in therapeutic development for Oral Mucositis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 1 and 6 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

Oral Mucositis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Oral Mucositis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Oral Mucositis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Oral Mucositis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Oral Mucositis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Oral Mucositis (Gastrointestinal)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize the emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Oral Mucositis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Oral Mucositis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Alivio Therapeutics Inc
  • BIOCND Inc
  • Clevexel Pharma SAS
  • Humanetics Corp
  • Lakewood-Amedex Inc
  • Matrix Biomed Inc
  • MORE
Introduction

Report Coverage
  • Oral Mucositis - Overview
  • Oral Mucositis - Therapeutics Development
Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
Oral Mucositis - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
Oral Mucositis - Companies Involved in Therapeutics Development
  • Alivio Therapeutics Inc
  • Allander Biotechnologies LLC
  • BIOCND Inc
  • Clevexel Pharma SAS
  • GlycoMira Therapeutics Inc
  • Humanetics Corp
  • Lakewood-Amedex Inc
  • Matrix Biomed Inc
  • Moberg Pharma AB
  • Spectrum Pharmaceuticals Inc
Oral Mucositis - Drug Profiles
  • BCD-600 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • bupivacaine hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CVXL-0095 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • genistein - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GM-0111 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • levoleucovorin calcium - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • lidocaine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Nu-3 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • pralatrexate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Recombinant Protein to Agonize FGFRs for Oral Mucositis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Recombinant Protein to Antagonize TGF beta for Immunology, Dermatology, Gastrointestinal and Musculoskeletal Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • suramin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Tempol - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Oral Mucositis - Dormant Projects
  • Oral Mucositis - Discontinued Products
  • Oral Mucositis - Product Development Milestones
Featured News & Press Releases
  • Dec 03, 2018: Spectrum Pharmaceuticals announces positive results from phase 2 trial evaluating use of oral Leucovorin to potentially Mitigate Mucositis in patients treated with FOLOTYN (pralatrexate)
  • May 02, 2018: Moberg Pharma: U.S. Patent Granted For BUPI
  • Sep 01, 2017: Canadian patent Granted for BUPI
  • Sep 01, 2017: Phase 2-results for BUPI Published
  • Oct 19, 2016: European Patent granted for BUPI
  • Jan 11, 2016: Moberg Pharma Announces Positive Phase II Data for BUPI
  • Jun 24, 2015: Moberg Pharma To Receive Eurostars Grant Of Eur 0.9 Million
  • Oct 28, 2014: First Patient Included in Phase ll Study of BUPI, a Novel Topical Formulation for Treatment of Oral Pain
Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact
  • Disclaimer
List of Tables
  • Number of Products under Development for Oral Mucositis, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Oral Mucositis - Pipeline by Alivio Therapeutics Inc, H2 2020
  • Oral Mucositis - Pipeline by Allander Biotechnologies LLC, H2 2020
  • Oral Mucositis - Pipeline by BIOCND Inc, H2 2020
  • Oral Mucositis - Pipeline by Clevexel Pharma SAS, H2 2020
  • Oral Mucositis - Pipeline by GlycoMira Therapeutics Inc, H2 2020
  • Oral Mucositis - Pipeline by Humanetics Corp, H2 2020
  • Oral Mucositis - Pipeline by Lakewood-Amedex Inc, H2 2020
  • Oral Mucositis - Pipeline by Matrix Biomed Inc, H2 2020
  • Oral Mucositis - Pipeline by Moberg Pharma AB, H2 2020
  • Oral Mucositis - Pipeline by Spectrum Pharmaceuticals Inc, H2 2020
  • Oral Mucositis - Dormant Projects, H2 2020
  • Oral Mucositis - Discontinued Products, H2 2020
List of Figures
  • Number of Products under Development for Oral Mucositis, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Top 10 Targets, H2 2020
  • Number of Products by Stage and Top 10 Targets, H2 2020
  • Number of Products by Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020
Note: Product cover images may vary from those shown
  • Alivio Therapeutics Inc
  • Allander Biotechnologies LLC
  • BIOCND Inc
  • Clevexel Pharma SAS
  • GlycoMira Therapeutics Inc
  • Humanetics Corp
  • Lakewood-Amedex Inc
  • Matrix Biomed Inc
  • Moberg Pharma AB
  • Spectrum Pharmaceuticals Inc
Note: Product cover images may vary from those shown
Adroll
adroll